BIOTECH STOCKS
Biogen Idec, Invitrogen lead sector gainers
By Val Brickates Kennedy, MarketWatch
Last update: 10:50 a.m. EST Feb. 6, 2008
BOSTON (MarketWatch) -- Drug stocks climbed Wednesday, as shares of biotech mainstay Biogen Idec gained in the wake of a strong financial results that showed fourth-quarter profit nearly doubled.
The Amex Biotechnology Index ($BTK: 740.19, +4.92, +0.7%) rose 0.7% to 740.43 and the Amex Pharmaceutical Index ($DRG:) added 0.4% to 313.34 in early action, as the sectors rebounded from a disappointing session on Tuesday.
Shares of Biogen Idec (BIIB:) hopped 3% to $62.07.
The Cambridge, Mass.-based drugmaker reported quarterly earnings jumped to 67 cents a share, up from 32 cents in the final three months of 2006, while revenue rocketed 26% to $893.3 million. Biogen also reiterated its 2008 profit forecast.
Meanwhile, shares of research tools provider Invitrogen Corp. (IVGN:) jumped 5% to $87.37.
Late Tuesday, the company said it's settled long-standing patent litigation against Agilent Technologies (A:).
Specific terms weren't disclosed, but the settlement calls for payments to be made on both sides, along with certain licensing agreements. In addition, Agilent will cease selling its RNase H minus RT products.
In addition, Invitrogen reported fourth-quarter earnings from continuing operations that jumped to 82 cents a share, up from the prior year's 46 cents. On an adjusted basis, earnings would have been $1.15 a share, up from 99 cents a share.
Biogen Idec, Invitrogen lead sector gainers
By Val Brickates Kennedy, MarketWatch
Last update: 10:50 a.m. EST Feb. 6, 2008
BOSTON (MarketWatch) -- Drug stocks climbed Wednesday, as shares of biotech mainstay Biogen Idec gained in the wake of a strong financial results that showed fourth-quarter profit nearly doubled.
The Amex Biotechnology Index ($BTK: 740.19, +4.92, +0.7%) rose 0.7% to 740.43 and the Amex Pharmaceutical Index ($DRG:) added 0.4% to 313.34 in early action, as the sectors rebounded from a disappointing session on Tuesday.
Shares of Biogen Idec (BIIB:) hopped 3% to $62.07.
The Cambridge, Mass.-based drugmaker reported quarterly earnings jumped to 67 cents a share, up from 32 cents in the final three months of 2006, while revenue rocketed 26% to $893.3 million. Biogen also reiterated its 2008 profit forecast.
Meanwhile, shares of research tools provider Invitrogen Corp. (IVGN:) jumped 5% to $87.37.
Late Tuesday, the company said it's settled long-standing patent litigation against Agilent Technologies (A:).
Specific terms weren't disclosed, but the settlement calls for payments to be made on both sides, along with certain licensing agreements. In addition, Agilent will cease selling its RNase H minus RT products.
In addition, Invitrogen reported fourth-quarter earnings from continuing operations that jumped to 82 cents a share, up from the prior year's 46 cents. On an adjusted basis, earnings would have been $1.15 a share, up from 99 cents a share.
Gruss Ice
Börsengewinne sind Schmerzengeld. Erst kommen die Schmerzen, dann das Geld...(A.K.)
Börsengewinne sind Schmerzengeld. Erst kommen die Schmerzen, dann das Geld...(A.K.)
